Ovarian Cancer Market Size, Share, Industry Trends And Forecast 2022-2027
The global Ovarian Cancer Market size reached US$ 1.68 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.34 Billion by 2027 exhibiting a CAGR of 11.40% during 2022-2027.
Covid-19 Impact:
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Industry Definition and Application:
Ovarian cancer represents a malignant tumor wherein irregular cells in the ovary begin to develop and multiply uncontrollably from the outer tissue lining or fallopian tubes, owing to mutagenic changes in the deoxyribonucleic acid (DNA). It can be treated through various diagnoses and drugs, such as antineoplastics, antirheumatics, mitotic, PARP, and VEGF/VEGFR inhibitors.
Request For Sample Report: https://www.imarcgroup.com/ovarian-cancer-market/requestsample
In addition, ovarian cancer treatment involves chemotherapy, surgery, hormone, radiation, and targeted therapies that aid in killing the cancer cells to provide relief from signs and systems. These therapeutics are conducted by medical practitioners across hospitals and specialty centers after determining several factors, such as the spread of the tumor, the general health of an individual, and the size and type of ovarian cancer.
Ovarian Cancer Market Trends and Drivers:
The escalating prevalence of epithelial, stromal, and germ cell cancer, especially among the female geriatric population, on account of the genetic mutation of BRCA2 or breast cancer gene 1 (BRCA1), is primarily driving the ovarian cancer market. Besides this, the elevating requirement for effective therapeutic drugs, including bevacizumab (Avastin) and pazopanib (Votrient), is further augmenting the market growth.
Moreover, the launch of several policies by the government bodies to sensitize consumers toward the treatments, symptoms, and benefits of early ovarian cancer diagnosis is also catalyzing the global market. Apart from this, the growing popularity of combination therapies in the healthcare sector to increase medicine efficacy and prevent drug resistance is acting as another significant growth-inducing factor.
Additionally, the ongoing patent expiration of branded medications has prompted pharmaceutical companies to launch novel recombinant drugs, which is also stimulating the market growth. Furthermore, the strategic collaborations among the leading players and the extensive research and development (R&D) activities to produce efficient therapeutic interventions are anticipated to propel the ovarian cancer market over the forecasted period.
| Ovarian Cancer Market Report Scope | |
| Report Coverage | Details |
| Market size value in 2021 | US$ 1.68 Billion |
| Market forecast in 2027 | US$ 3.34 Billion |
| Growth Rate | CAGR of 11.40% from 2022 to 2027 |
| Base year for estimation | 2021 |
| Historical data | 2016-2021 |
| Forecast period | 2022-2027 |
| Report coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments covered | Type, Treatment Type And End User |
| Regional scope | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Key companies profiled | AbbVie Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Pfizer Inc. and Teva Pharmaceutical Industries Ltd. |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Click here to view detailed information with table of content: https://www.imarcgroup.com/ovarian-cancer-market
Report Segmentation:
The report has been segmented the market into following categories:
Breakup by Type:
- Epithelial Ovarian Cancer
- Germ Cell Ovarian Cancer
- Stromal Cell Ovarian Cancer
Breakup by Treatment Type:
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Surgery
- Others
Breakup by End User:
- Hospitals
- Homecare
- Speciality Centre
- Others
By Geography:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
List of Major Key Players:
The major players in the market are AbbVie Inc., Amneal Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
0
